Celsion Featured On Front Page of Investor's Business Daily for Advanced Therapy to Help Common Prostate Woes From Aging.COLUMBIA, Md.--(BUSINESS WIRE)--Nov. 17, 1999-- -- Company has FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. Approval to Begin Expanded Study of its IDE-approved System -- Celsion Corporation (OTC BB: CELN) was featured today on the front page of Investor's Business Daily Investor's Business Daily (IBD) is a national newspaper in the United States, published Monday through Friday, that covers international business, finance, and the global economy. Founded in 1984 by William O'Neil, its headquarters are in Los Angeles, California. for its advanced benign prostatic hyperplasia benign prostatic hyperplasia n. Abbr. BPH A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine. (BPH) treatment system, which is designed to treat this common prostate condition that affects 50 percent of men over the age of 50. Earlier this year the Company successfully completed Phase I clinical studies of its BPH system, which has an Investigational Device Exemption An Investigational Device Exemption (IDE) allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data required to support a Premarket Approval (PMA) application or a Premarket Notification [510(k)] submission to Food and (IDE) from the U.S. Food and Drug Administration (FDA). Celsion also received approval this year from the FDA to begin an expanded study of its BPH treatment with a revised design to shorten the treatment period. Today's article in Investor's Business Daily drew attention to the prevalence of BPH and the fact that men suffering from the condition now have access to new treatments that "dramatically impact your quality of life." as compared to common treatments that involve daily medication or surgery. In the feature on BPH, the journal also highlighted Celsion's system for its unique design to use microwave thermotherapy in a walk-in, one-hour treatment that, unlike many competitors' systems, does not require a post-therapy catheter. Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and other diseases using focused heat delivered by patented microwave technology. Clinicals and further development of the Company's treatment systems are being conducted by leading institutions such as the Columbia Hospital (a Columbia/HCA Healthcare member), Duke University, Duke University Medical Center, Harbor UCLA Medical Center UCLA Medical Center is a hospital located on the campus of the University of California, Los Angeles in Los Angeles, California. It is rated as one of the top three hospitals in the United States and is the top hospital on the West Coast according to US News & World Report. , Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, and Montefiore Medical Center Montefiore Medical Center, in the Bronx, New York, is the university hospital of the Albert Einstein College of Medicine. The hospital, named after Moses Montefiore, is one of the 50 largest employers in New York State [1]. . Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, possible changes in cost of materials, expense items, capital expenditures, capital structure, and other financial items; introduction of new products and possible acquisitions of assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion